Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
Sands Capital Life Sciences Pulse Fund III (DE), L.P. - 06 Feb 2026 SCHEDULE 13G Report for SpyGlass Pharma, Inc. Common Stock, $0.00001 par value per share
- Filing manager
- Sands Capital Life Sciences Pulse Fund III (DE), L.P.
- Reporting owner
- SANDS FRANK M.
- Beneficially owned shares
- 2,500,012 shares
- Large-stake signal
-
Ownership
7.8%Beneficial ownership of this reported class.
Shares
2,500,012 sharesShares beneficially owned as disclosed.
Event date
06 Feb 2026Date tied to the ownership event or amendment.
Accepted by SEC
13 Feb 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 7.8%
- Shares outstanding
- 32,051,436 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 13 Feb 2026, 11:36:01 UTC
- Event date
- 06 Feb 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
1 source field
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Sands Capital Life Sciences Pulse Fund III (DE), L.P. disclosed 7.8% ownership in SpyGlass Pharma, Inc. Common Stock, $0.00001 par value per share on 06 Feb 2026.
Key facts
- Sands Capital Life Sciences Pulse Fund III (DE), L.P. filed SCHEDULE 13G for SpyGlass Pharma, Inc. Common Stock, $0.00001 par value per share.
- Disclosed ownership: 7.8%.
- Date of event: 06 Feb 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2026, 11:36.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (4)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund III (DE), L.P. | 1.3% | 420,797 | 0 | 420,797 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund III (DE), L.P. | |
| Sands Capital Life Sciences Pulse Fund III-Holdings, L.P. | 6.5% | 2,079,215 | 0 | 2,079,215 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund III-Holdings, L.P. | |
| Sands Capital Alternatives, LLC | 1.3% | 420,797 | 0 | 420,797 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel | |
| SANDS FRANK M. | 7.8% | 2,500,012 | 0 | 2,500,012 | /s/ Frank M. Sands | Frank M. Sands |
CIK / CUSIP context first